These results suggested that glioma patients with low PVT1 expression and high HAR1A expression could benefit more from chemotherapy and radiotherapy; up-regulated PVT1 and down-regulated HAR1A might be the indicators of poor response to adjuvant chemoradiotherapy. Here, HAR1A is linked to central nervous system cancer.